Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 46, Issue 5, 2008, Pages 524-533

  Gilger, Mark A ^a,f   Tolia, Vasundhara ^b   Vandenplas, Yvan ^c   Youssef, Nader N ^d   Traxler, Barry ^e   Illueca, Marta ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d Atlantic Health   (United States)

^e ASTRAZENECA   (United Kingdom)

^f Texas Children's Hospital   (United States)

Author keywords

Esomeprazole; Gastroesophageal reflux disease; Proton pump inhibitor; Safety

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; ESOMEPRAZOLE; MAGNESIUM HYDROXIDE; ENZYME INHIBITOR; OMEPRAZOLE;

ANAMNESIS; ARTHRALGIA; ARTICLE; ASTHENIA; CHILD; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERYTHEMA MULTIFORME; EYE SWELLING; FEMALE; FEVER; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; INFANT; LABORATORY TEST; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHOOL CHILD; SCORING SYSTEM; SOMNOLENCE; SORE THROAT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; PATHOLOGY; SAFETY;

CHILD; CHILD, PRESCHOOL; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMANS; INFANT; MALE; OMEPRAZOLE; SAFETY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 48249111016     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318176b2cb     Document Type: Article

References (30)

1. Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Pediatr Drugs 2002;4:673-85.
2. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32(Suppl 2):Sl-31.
3. Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 2000;154:150-4.
4. Orenstein SR, Shalaby TM, Kelsey SF, et al. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol 2006;101:628-40.
5. El-Serag HB, Gilger M, Carter J, et al. Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gasrtroen-terol 2004;99:806-12.
6. Waring JP, Feiler MJ, Hunter JG, et al. Childhood gastroesophageal reflux symtpoms in adult patients. J Pediatr Gastroenterol Nutr 2002;35:334-8.
7. El-Serag HB, Gilger M, Kuebeler M, et al. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001;121:1294-9.
8. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
9. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
10. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
11. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
12. Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4: 1452-8.
13. Gold B, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:520-9.
14. Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28:1868-76.
15. Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14: 1267-72.
16. Gilger MA, El-Serag HB, Dietrich CL, et al. Endoscopic manifestations of erosive esophagitis in children [abstract]. Gastrointest Endosc 2004;59:143.
17. Squires RH, Colletti RB. Indications for pediatric gastrointestinal endoscopy: a medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1996;23:107-10.
18. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45: 172-80.
19. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
20. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6.
21. Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006;42:384-91.
22. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S308-18.
23. Tolia V, Fitzgerald J, Hassall E, et al. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S300-7.
24. Madrazo-de la Garza A, Dibildox M, Vargas A, et al. Efficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in children. J Pediatr Gastroenterol Nutr 2003;36: 261-5.
25. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 2000;137:800-7.
26. Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr 2006;45:741-9.
27. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007;150:262-7.
28. Gupta SK, Fitzgerald JF, Chong SK, et al. Vertical lines in distal esophageal mucosa (VLEM): a true endoscopic manifestation of esophagitis in children? Gastrointest Endosc 1997;45: 485-9.
29. National Center for Health Statistics. Clinical Growth Charts. http://www.cdc.gov/growthcharts. Accessed October 19, 2006.
30. Moustafellos E, Illueca M. Failure to thrive: The endoscopic view [abstract]. J Pediatr Gastroenterol Nutr 1997;25:464.